Physician profile
Mohammad I Khan
NPI 1790710481
$11,350.53
in general payments reported to CMS, 2019-2025
66 companies · $1,929 in 2025
The $1,929 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,885 · 2020: $871 · 2021: $1,329 · 2022: $1,872 · 2023: $1,476 · 2024: $1,988 · 2025: $1,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,370 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,370.34 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,137.16 | 2019-2025 | |
| Pfizer INC. | $932.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $660.72 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $659.89 | 2019-2025 | Opdivo, Breyanzi |
| Daiichi Sankyo INC. | $578.21 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Celgene Corporation | $513.61 | 2019-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $441.71 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Genzyme Corporation | $396.93 | 2019-2025 | |
| Amgen INC. | $381.68 | 2019-2023 | Lumakras |
| Seagen INC. | $373.24 | 2019-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $363.37 | 2019-2025 | Tagrisso |
| Eisai INC. | $357.57 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $280.20 | 2021-2025 | Libtayo |
| Beigene USA, INC. | $245.32 | 2020-2024 | Brukinsa |
| Glaxosmithkline, LLC. | $240.88 | 2020-2025 | Ojjaara, Blenrep |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.